gatifloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibacterials, nalidixic acid derivatives 1280 112811-59-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gatifloxacin anhydrous
  • gatifloxin
  • gatifloxacin
  • gatifloxacin hydrate
A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
  • Molecular weight: 375.40
  • Formula: C19H22FN3O4
  • CLOGP: -0.01
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 82.11
  • ALOGS: -2.77
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 96 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.80 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 28, 2003 FDA ALLERGAN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic reaction 133.36 28.69 50 1202 54005 50549867
Hypoglycaemia 101.66 28.69 41 1211 53540 50550332
Drug hypersensitivity 100.08 28.69 67 1185 250943 50352929
Drug intolerance 60.64 28.69 47 1205 219057 50384815
Toxic anterior segment syndrome 45.62 28.69 10 1242 1555 50602317
Corneal disorder 45.24 28.69 10 1242 1616 50602256
Visual acuity reduced 40.10 28.69 16 1236 20123 50583749
Hyperglycaemia 39.96 28.69 19 1233 36386 50567486
Keratitis 35.97 28.69 9 1243 2476 50601396
Endophthalmitis 34.54 28.69 9 1243 2907 50600965
Cataract 32.48 28.69 18 1234 47282 50556590

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 261.40 25.22 101 1706 48245 29524475
Hyperglycaemia 137.58 25.22 58 1749 34229 29538491
Intraocular pressure increased 77.82 25.22 23 1784 4766 29567954
Clostridium colitis 76.21 25.22 17 1790 1150 29571570
Visual acuity reduced 69.09 25.22 28 1779 14848 29557872
Blood glucose decreased 60.47 25.22 24 1783 12045 29560675
Corneal oedema 39.75 25.22 10 1797 1132 29571588
Blood glucose increased 39.52 25.22 31 1776 58953 29513767
Retinal haemorrhage 33.62 25.22 12 1795 4492 29568228
International normalised ratio increased 33.39 25.22 25 1782 44347 29528373
Corneal opacity 30.91 25.22 7 1800 506 29572214
Toxic anterior segment syndrome 30.80 25.22 8 1799 1028 29571692
Corneal endotheliitis 26.50 25.22 4 1803 28 29572692
Eye pain 25.58 25.22 13 1794 11582 29561138
Vitreous haemorrhage 25.54 25.22 8 1799 2005 29570715

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 339.44 24.96 130 2525 89762 64406315
Hyperglycaemia 166.36 24.96 70 2585 60898 64435179
Intraocular pressure increased 100.29 24.96 29 2626 8273 64487804
Anaphylactic reaction 96.90 24.96 50 2605 68614 64427463
Visual acuity reduced 83.45 24.96 34 2621 27107 64468970
Corneal disorder 63.00 24.96 15 2640 2012 64494065
Corneal oedema 55.82 24.96 14 2641 2329 64493748
Toxic anterior segment syndrome 55.26 24.96 14 2641 2425 64493652
Clostridium colitis 54.78 24.96 14 2641 2511 64493566
Blood glucose decreased 54.51 24.96 24 2631 23099 64472978
Drug hypersensitivity 46.66 24.96 53 2602 237762 64258315
Drug intolerance 45.82 24.96 47 2608 187945 64308132
Corneal opacity 40.44 24.96 9 2646 896 64495181
Endophthalmitis 40.23 24.96 13 2642 5352 64490725
Vision blurred 36.49 24.96 30 2625 90286 64405791
Blood glucose increased 34.34 24.96 30 2625 98043 64398034
Keratitis fungal 34.03 24.96 6 2649 179 64495898
Corneal endotheliitis 32.45 24.96 5 2650 63 64496014
Cataract subcapsular 29.82 24.96 7 2648 882 64495195
Eye pain 28.03 24.96 17 2638 31608 64464469
Vitreous opacities 27.97 24.96 6 2649 503 64495574
Conjunctival hyperaemia 27.42 24.96 9 2646 3890 64492187
International normalised ratio increased 27.26 24.96 24 2631 79143 64416934
Eye inflammation 25.48 24.96 9 2646 4848 64491229
Macular oedema 25.46 24.96 9 2646 4858 64491219

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01MA16 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
QUINOLONE ANTIBACTERIALS
Fluoroquinolones
ATC S01AE06 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Fluoroquinolones
FDA CS M0023650 Quinolones
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:50750 inhibitors of type II topoisomerase
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D009883 Ophthalmic Solutions
MeSH PA D019999 Pharmaceutical Solutions
MeSH PA D059005 Topoisomerase II Inhibitors
FDA EPC N0000175937 Quinolone Antimicrobial

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Gonorrhea of rectum indication 42746002
Pneumonia due to Mycoplasma pneumoniae indication 46970008
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Haemophilus influenzae pneumonia indication 70036007
Acute bacterial sinusitis indication 75498004
Bacterial conjunctivitis indication 128350005 DOID:9700
Pneumococcal pneumonia indication 233607000
Chlamydial pneumonia indication 233609002
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Bacterial urinary infection indication 312124009
Infection due to Staphylococcus aureus indication 406602003
Acute exacerbation of chronic bronchitis indication 425748003
Urinary tract infection caused by Klebsiella indication 369001000119100
Moraxella Catarrhalis Chronic Bronchitis indication
E. Coli Pyelonephritis indication
Haemophilus Parainfluenzae Chronic Bronchitis indication
Legionella Pneumophila Pneumonia indication
Moraxella Catarrhalis Pneumonia indication
Staphylococcus Chronic Bronchitis indication
Complicated Proteus UTI indication
Streptococcus Pneumoniae Chronic Bronchitis indication
Skin and Skin Structure Streptococcus Infection indication
Haemophilus Influenzae Chronic Bronchitis indication
Haemophilus Parainfluenzae Pneumonia indication
Acute tuberculosis off-label use 25629007
Pulmonary tuberculosis off-label use 154283005 DOID:2957




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.23 acidic
pKa2 8.39 Basic
pKa3 1.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
DNA topoisomerase 4 Enzyme INHIBITOR CHEMBL CHEMBL
DNA gyrase Enzyme INHIBITOR CHEMBL CHEMBL
DNA topoisomerase 4 subunit A Enzyme IC50 5.92 CHEMBL
DNA gyrase subunit A Enzyme IC50 5.03 CHEMBL
DNA gyrase Enzyme IC50 6.30 CHEMBL

External reference:

IDSource
4021187 VUID
N0000148634 NUI
D00589 KEGG_DRUG
4021187 VANDF
CHEBI:5280 CHEBI
GFN PDB_CHEM_ID
CHEMBL31 ChEMBL_ID
CHEMBL428581 ChEMBL_ID
CHEMBL251670 ChEMBL_ID
10816 IUPHAR_LIGAND_ID
DB01044 DRUGBANK_ID
L4618BD7KJ UNII
5379 PUBCHEM_CID
1546025 RXNORM
8587 MMSL
d04504 MMSL
007995 NDDF
116349004 SNOMEDCT_US
371238005 SNOMEDCT_US
D000077734 MESH_DESCRIPTOR_UI
C0753645 UMLSCUI
7423 INN_ID
180200-66-2 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZYMAXID HUMAN PRESCRIPTION DRUG LABEL 1 0023-3615 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 25 sections
ZYMAR HUMAN PRESCRIPTION DRUG LABEL 1 0023-9218 SOLUTION/ DROPS 3 mg OPHTHALMIC EXPORT ONLY 1 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 13668-526 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 20 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 13668-526 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 20 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50383-189 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 23 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50383-189 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 23 sections
ZYMAXID HUMAN PRESCRIPTION DRUG LABEL 1 54868-6303 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 25 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 57297-435 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 24 sections
gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 60758-615 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA authorized generic 25 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 61314-672 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 23 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 68180-435 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 24 sections